Results 331 to 340 of about 12,986,553 (373)
Some of the next articles are maybe not open access.
Current Pharmaceutical Design, 1996
Thrombin occupies a central position in thrombus formation and eventually has been a target to develop anticoagulant agents. Although both heparin and warfarin have been used as anticoagulants, a more useful, ideal anticoagulant is desired at bedside.
Satoshi Kunitada, Takayasu Nagahara
openaire +1 more source
Thrombin occupies a central position in thrombus formation and eventually has been a target to develop anticoagulant agents. Although both heparin and warfarin have been used as anticoagulants, a more useful, ideal anticoagulant is desired at bedside.
Satoshi Kunitada, Takayasu Nagahara
openaire +1 more source
Seminars in Thrombosis and Hemostasis, 2019
Choices for monitoring of unfractionated heparin (UFH) anticoagulation in extracorporeal membrane oxygenation (ECMO) patients include activated clotting time, activated partial thromboplastin time, reaction times of viscoelastic tests, and anti-factor Xa
M. Ranucci +5 more
semanticscholar +1 more source
Choices for monitoring of unfractionated heparin (UFH) anticoagulation in extracorporeal membrane oxygenation (ECMO) patients include activated clotting time, activated partial thromboplastin time, reaction times of viscoelastic tests, and anti-factor Xa
M. Ranucci +5 more
semanticscholar +1 more source
1992
The assembly and function of the prothrombinase complex on the bovine and human platelet membrane is mediated through binding interactions in which factor Va bound to the platelet surface forms at least part of the "receptor" for factor Xa in a 1:1 stoichiometric complex. A model depicting these binding interactions is shown in Fig. 12.
P B, Tracy, M E, Nesheim, K G, Mann
openaire +2 more sources
The assembly and function of the prothrombinase complex on the bovine and human platelet membrane is mediated through binding interactions in which factor Va bound to the platelet surface forms at least part of the "receptor" for factor Xa in a 1:1 stoichiometric complex. A model depicting these binding interactions is shown in Fig. 12.
P B, Tracy, M E, Nesheim, K G, Mann
openaire +2 more sources
Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage.
New England Journal of MedicineBACKGROUND Patients with acute intracerebral hemorrhage who are receiving factor Xa inhibitors have a risk of hematoma expansion. The effect of andexanet alfa, an agent that reverses the effects of factor Xa inhibitors, on hematoma volume expansion has ...
Stuart J. Connolly +40 more
semanticscholar +1 more source
2023
This chapter describes factor Xa as a key enzyme involved in thrombosis and clot formation. It considers factor Xa inhibitors as potential anticoagulants for the treatment of deep-vein thrombosis and pulmonary embolism. It also highlights the first factor Xa inhibitors to reach the market and covers the design process that led to the discovery of ...
openaire +1 more source
This chapter describes factor Xa as a key enzyme involved in thrombosis and clot formation. It considers factor Xa inhibitors as potential anticoagulants for the treatment of deep-vein thrombosis and pulmonary embolism. It also highlights the first factor Xa inhibitors to reach the market and covers the design process that led to the discovery of ...
openaire +1 more source
Perspectives on Factor Xa Inhibition
Current Medicinal Chemistry, 2001Blood coagulation involves a complex cascade of enzymatic reactions, ultimately generating fibrin, the basis of all blood clots. This cascade is comprised of two arms, the intrinsic and extrinsic pathways which converge at factor Xa to form the common pathway.
R, Rai +3 more
openaire +2 more sources
Perspectives in Drug Discovery and Design, 1994
Factor Xa is the serine protease that activates prothrombin to yield thrombin. Inhibitors of factor Xa play a crucial role in curtailing thrombin generation. Two key factor Xa inhibitors that are found in blood are antithrombin III and tissue factor pathway inhibitor.
openaire +1 more source
Factor Xa is the serine protease that activates prothrombin to yield thrombin. Inhibitors of factor Xa play a crucial role in curtailing thrombin generation. Two key factor Xa inhibitors that are found in blood are antithrombin III and tissue factor pathway inhibitor.
openaire +1 more source
Anti-factor Xa (Anti-Xa) Assay
2013The anti-factor Xa (anti-Xa) assay is a functional assay that facilitates the measurement of antithrombin (AT)-catalyzed inhibition of factor Xa by unfractionated heparin (UFH) and direct inhibition of factor Xa by low-molecular-weight heparin (LMWH) (Kitchen, Br J Haematol 111:397-406, 2000; Walenga et al., Semin Thromb Hemost 11:17-25, 1985; Levine ...
openaire +2 more sources
Anthranilamide inhibitors of factor Xa
Bioorganic & Medicinal Chemistry Letters, 2007SAR about the B-ring of a series of N(2)-aroyl anthranilamide factor Xa (fXa) inhibitors is described. B-ring o-aminoalkylether and B-ring p-amine probes of the S1' and S4 sites, respectively, afforded picomolar fXa inhibitors that performed well in in vitro anticoagulation assays.
David, Mendel +20 more
openaire +2 more sources
2023
Abstract Oral factor Xa (FXa) inhibitors exert their antithrombotic effects and increase the risk of bleeding by their effects on the coagulation system. The oral direct FXa inhibitors are highly potent, reversible active-site inhibitors of FXa with good bioavailability, rapid onset, and used in a daily standard dose without laboratory ...
Agneta Siegbahn +3 more
openaire +1 more source
Abstract Oral factor Xa (FXa) inhibitors exert their antithrombotic effects and increase the risk of bleeding by their effects on the coagulation system. The oral direct FXa inhibitors are highly potent, reversible active-site inhibitors of FXa with good bioavailability, rapid onset, and used in a daily standard dose without laboratory ...
Agneta Siegbahn +3 more
openaire +1 more source